Picture loading failed.

Pre-Made Obiltoxaximab biosimilar, Whole Mab: Anti-Anthrax Protective Antigen therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Obiltoxaximab, sold under the brand name Anthim, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-384-1mg 1mg 3090
GMP-Bios-ab-384-10mg 10mg Inquiry
GMP-Bios-ab-384-100mg 100mg Inquiry
GMP-Bios-ab-384-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Obiltoxaximab biosimilar, Whole Mab: Anti-Anthrax Protective Antigen therapeutic antibody
INN Name Obiltoxaximab
TargetAnthrax Protective Antigen
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesElusys Therapeutics
Conditions ApprovedAnthrax
Conditions Activena
Conditions Discontinuedna
Development Techna